Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events-Reply

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Vanderbilt University School of Medicine, Nashville, Tennessee.
³ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.

Comment

Douglas B Johnson et al. JAMA Oncol. 2021.

. 2021 Oct 1;7(10):1574-1575.

doi: 10.1001/jamaoncol.2021.2957.

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Vanderbilt University School of Medicine, Nashville, Tennessee.
³ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.

No abstract available

Comment on

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Patrinely JR Jr, et al. JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051. JAMA Oncol. 2021. PMID: 33764387 Free PMC article.
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events.
Rassy E, Pistilli B, Robert C. Rassy E, et al. JAMA Oncol. 2021 Oct 1;7(10):1573-1574. doi: 10.1001/jamaoncol.2021.2954. JAMA Oncol. 2021. PMID: 34383012 No abstract available.